Reviva to Participate in Fireside Chat at A.G.P.’s Annual Healthcare Company Showcase

Reviva (OTCQB: RVPH) announced that Founder, President and CEO Laxminarayan Bhat, PhD, will join a fireside chat with equity research analyst Jim Molloy at A.G.P.’s Annual Healthcare Company Showcase on Wednesday, May 20, 2026, from 2:40–3:00 PM ET.

Rhea-AI Summary

Reviva (OTCQB: RVPH) announced that Founder, President and CEO Laxminarayan Bhat, PhD, will join a fireside chat with equity research analyst Jim Molloy at A.G.P.’s Annual Healthcare Company Showcase on Wednesday, May 20, 2026, from 2:40–3:00 PM ET. Investors can register to watch the session online.

Argus May 18 session

+23.31% close to close Open Argus

Details

News Market Reaction – RVPH

On May 18, the day this news came out, RVPH closed 23.31% above the previous close.

Data tracked by StockTitan Argus for the May 18 session.

Market Context

On May 18, the day this news came out, the stock closed 23.3% above the previous close. A strong pos...

Analysis

On May 18, the day this news came out, the stock closed 23.3% above the previous close. A strong positive reaction aligns with how RVPH has sometimes traded around communication-focused events, such as prior fireside chats and shareholder letters. With shares at $0.3325 and down 98.57% from the $23.20 52-week high, any sharp bounce could reflect short-term positioning and prior volatility patterns. Investors have also seen positive moves after financings, suggesting sentiment can shift quickly once funding and trial visibility improve.

Key Figures

Conference date: May 20, 2026 Fireside chat time: 2:40–3:00 PM ET Current share price: $0.3325 +1 more

Conference date

May 20, 2026

A.G.P.’s Annual Healthcare Company Showcase

Fireside chat time

2:40–3:00 PM ET

Scheduled discussion with equity research analyst

Current share price

$0.3325

Prior to publication of conference participation news

52-week range

$0.262–$23.20

Shares trading far below 52-week high pre-announcement

Historical Context

5 past events · Latest: May 13

5 events

1. May 13

   Earnings and pipeline

   24h Move

   +10.8%

   Narrower loss, higher cash, patent steps and RECOVER-2 planning for brilaroxazine.

2. Apr 23

   Investor fireside chat

   24h Move

   -4.2%

   Announcement of A.G.P.-hosted discussion on brilaroxazine milestones and outlook.

3. Apr 15

   Shareholder letter

   24h Move

   +3.4%

   Update on financing, cash runway into 2027, and RECOVER-2 clinical timelines.

4. Mar 30

   Full-year earnings

   24h Move

   -11.0%

   Reported 2025 net loss and need for second Phase 3 trial per FDA feedback.

5. Mar 23

   Public equity offering

   24h Move

   +11.6%

   Dilutive $10M equity and warrant offering to fund RECOVER-2 and operations.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

central nervous system (cns), cardiometabolic, otcqb

3 terms

central nervous system (cns) medical

"unmet medical needs in the areas of central nervous system (CNS), inflammatory"

The central nervous system (CNS) is the part of the body that includes the brain and spinal cord, acting as the control center for processing information and directing actions. It is essential for coordinating all bodily functions, from movement to thinking. For investors, understanding the CNS is important because it illustrates how complex systems—like markets or organizations—rely on core components to operate smoothly.

cardiometabolic medical

"inflammatory and cardiometabolic diseases, today announced that Laxminarayan"

Cardiometabolic describes health conditions that affect the heart and the body’s metabolism—most commonly heart disease, high blood pressure, type 2 diabetes and obesity—that often occur together and share common causes. Investors care because these linked conditions drive large, predictable demand for drugs, medical devices and long-term care, and changes in treatment options, guidelines or costs can materially affect healthcare company revenues and government spending much like a problem in an engine and its fuel system impacts the whole vehicle.

otcqb financial

"Reviva Pharmaceuticals Holdings, Inc. (OTCQB: RVPH) (“Reviva,” the “Company”"

OTCQB is a tier of the over‑the‑counter (OTC) market where smaller or developing companies list their shares for trading without being on a major stock exchange. Think of it like a well‑kept side street market: companies must meet basic reporting and transparency checks so investors get more information than the lowest OTC tier, but trading is usually less liquid and riskier than on big exchanges. Investors care because OTCQB listings can offer early access to growth stories but come with higher price swings and greater chance of limited resale options.

View in glossary

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CUPERTINO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (OTCQB: RVPH) (“Reviva,” the “Company” “we” or “us”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, PhD, Founder, President, and CEO of Reviva, will participate in a fireside chat with equity research analyst Jim Molloy at A.G.P.’s Annual Healthcare Company Showcase being held Wednesday, May 20, 2026.

Fireside Chat Details:
Time: 2:40-3:00 PM ET
Date: Wednesday, May 20, 2026

Investors can register for the conference and view the fireside chat here.

About Reviva 
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.

Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD 
www.revivapharma.com

Investor Relations Contact:
LifeSci Advisors, LLC
PJ Kelleher
pkelleher@lifesciadvisors.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Reviva (OTCQB: RVPH) presenting at A.G.P.’s Annual Healthcare Company Showcase 2026?

Reviva is scheduled for a fireside chat on Wednesday, May 20, 2026, from 2:40–3:00 PM ET. According to Reviva, investors can register for the conference online and view the session virtually.

Who will represent Reviva (OTCQB: RVPH) at the A.G.P. Healthcare Company Showcase fireside chat?

Reviva will be represented by Founder, President and CEO Laxminarayan Bhat, PhD. According to Reviva, he will participate in a fireside chat with equity research analyst Jim Molloy during the May 20, 2026 session.

What is the format of Reviva’s appearance at A.G.P.’s Annual Healthcare Company Showcase 2026?

Reviva’s appearance will be a fireside chat with equity research analyst Jim Molloy. According to Reviva, the discussion is scheduled for May 20, 2026, from 2:40–3:00 PM ET as part of the conference program.

How can investors watch Reviva’s May 20, 2026 fireside chat at A.G.P.’s Healthcare Showcase?

Investors can register for the conference and view Reviva’s fireside chat online. According to Reviva, registration provides access to the May 20, 2026 session scheduled between 2:40 PM and 3:00 PM Eastern Time.

What type of company is Reviva (OTCQB: RVPH) participating in A.G.P.’s 2026 Healthcare Showcase?

Reviva is described as a late-stage pharmaceutical company focused on CNS, inflammatory and cardiometabolic diseases. According to Reviva, its therapies seek to address unmet medical needs in these areas as it engages investors at the A.G.P. conference.